Big Biogen boost on Alzheimer’s news could win back biotech investors
By Lewis Krauskopf
NEW YORK (Reuters) – The approval by U.S. regulators on Monday of a Biogen Inc drug to treat Alzheimer’s disease could reinvigorate investor interest more broadly in biotech and pharmaceutical shares that have struggled in 2021.
Biogen…
